<DOC>
	<DOCNO>NCT02003560</DOCNO>
	<brief_summary>The purpose study determine phase II clinical trial whether accelerate partial breast irradiation breast conserve surgery use 3 dimensional external beam radiotherapy ( 3D-CRT ) intensity modulate radiotherapy ( IMRT ) low-risk invasive breast cancer patient safe without cause serious late radiation side-effects .</brief_summary>
	<brief_title>Accelerated Partial Breast Irradiation With 3D-CRT IMRT</brief_title>
	<detailed_description>It sequential phase II trial . Eligible patient breast conserve surgery ( BCS ) treat accelerate partial breast irradiation ( APBI ) use three-dimensional conformal radiotherapy ( 3D-CRT ) first 45 patient intensity modulate radiotherapy ( IMRT ) second 45 patient . Primary end-point study : late radiation side-effects 5 year . Early stop criterion : Not use primary end-point late side-effects . Interim analysis : Not plan Secondary end-points : cosmetic result , quality life , local recurrence-free survival , regional recurrence free survival , distant metastasis free survival , relapse free survival , overall survival , cancer specific survival . Null-hypothesis primary end-point : The incidence severe ( &gt; G2 ) late radiation side-effects APBI use 3D-CRT IMRT exceed 10 % . Stratification : - treatment delivery : 3D-CRT - first 45 patient ; IMRT - second 45 patient - bra capsize : Capsize A-B ; C ; D-D+ Treatment intervention : 9 x 4.1 Gy APBI use 3D-CRT ( first 45 patient ) IMRT ( second 45 patient ) deliver within 5 day , use twice-a-day fractionation . Clinical target volume ( CTV ) Planning target volume ( PTV ) definition : CTV = excision cavity + 20 mm minus actual pathological surgical margin mm PTV = CTV + 5 mm direction Follow-up : - ECOG PS , physical examination ( inspection palpation ) , registration side-effects ( RTOG ( Radiation Therapy Oncology Group ) EORTC ( European Organization Research Treatment Cancer ) ) early late radiation morbidity score scheme ) cosmetic result ( use Harvard scale ) : 7-14 day RT , every 3 month 2 year , every 6 month 5 year . - Mammography : 6 , 12 , 18 , 24 month , annually thereafter - Quality life questionnaire ( QLQ ) ( e.g . EORTC ( European Organization Research Treatment Cancer ) QLQ-30 Breast ( BR ) -23 ) RT , 7-14 day RT , 3 , 6 , 12 month , annually thereafter - digital photography : treatment , 7-14 day treatment , yearly thereafter</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>previous breast conserving surgery within 12 week ( case adjuvant chemotherapy within 28 day completion chemotherapy ) patient age &gt; 40 year ECOG performance status : 01 life expectancy &gt; 5 year invasive ductal , papillary , mucinous , medullary tubular carcinoma unifocal tumor pathological tumor size &lt; = 30 mm pathological negative axillary nodal status axillary dissection sentinel lymph node biopsy surgical clip tumor bed pathological surgical free margin least 2 mm write informed consent patient Stage IIIIV multifocal tumor extensive intraductal component ( EIC ) ductal lobular carcinoma situ ( DCIS LCIS ) invasive lobular cancer ( ILC ) lymphvascular invasion ( LVI ) contralateral breast cancer history treatment previous breast cancer lactation breast feed woman Pagetdisease nipple psychiatric disorder increase radiosensitivity ( e.g . collagen vascular disease )</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>breast conserving therapy</keyword>
	<keyword>accelerate partial breast irradiation</keyword>
	<keyword>3D conformal radiotherapy</keyword>
	<keyword>intensity modulate radiotherapy</keyword>
</DOC>